Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation

Sachiko Hirosue, Iraklis C. Kourtis, André J. van der Vlies, Jeffrey A. Hubbell, Melody A. Swartz

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Vaccines aiming to activate cytotoxic T cells require cross-presentation of exogenous antigen by antigen-presenting cells (APCs). We recently developed a synthetic nanoparticle vaccine platform that targets lymph node-resident dendritic cells (DCs), capable of mounting an immune response to conjugated antigen. Here, we explore routes of processing and the efficiency of MHC I cross-presentation of OVA peptides conjugated using both reducible and non-reducible linkages, exploring the hypothesis that reduction-sensitive conjugation will lead to better antigen cross-presentation. Both clathrin and macropinocytic pathways were implicated in nanoparticle uptake by colocalization and inhibitor studies. Cross-presentation by DCs was demonstrated by direct antibody staining and in vitro stimulation of CD8+ T cells from OT-I mice and was indeed most efficient with the reduction-sensitive conjugation. Similarly, we observed IFN-γ production by CD4+ T cells from OT-II mice. Finally, immunization with the OVA peptide-bearing nanoparticles resulted in in vivo proliferation and IFN-γ production by adoptively transferred CD8+ OT-I T cells and was also most efficient with reduction-sensitive linking of the peptide antigen. These results demonstrate the relevance of the poly(propylene sulfide) nanoparticle vaccine platform and antigen conjugation scheme for activating both cytotoxic and helper T cell responses.

Original languageEnglish
Pages (from-to)7897-7906
Number of pages10
JournalVaccine
Volume28
Issue number50
DOIs
StatePublished - Nov 23 2010
Externally publishedYes

Fingerprint

Cross-Priming
propylene
nanoparticles
dendritic cells
sulfides
Disulfides
Nanoparticles
Dendritic Cells
T-lymphocytes
peptides
antigens
T-Lymphocytes
Antigens
Peptides
vaccines
Vaccines
Clathrin
Synthetic Vaccines
Antigen Presentation
Antigen-Presenting Cells

Keywords

  • Cross-presentation
  • Macropinocytosis
  • Nanoparticles
  • Reducible
  • Vinyl sulfone

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides : Cross-presentation and T cell activation. / Hirosue, Sachiko; Kourtis, Iraklis C.; van der Vlies, André J.; Hubbell, Jeffrey A.; Swartz, Melody A.

In: Vaccine, Vol. 28, No. 50, 23.11.2010, p. 7897-7906.

Research output: Contribution to journalArticle

Hirosue, Sachiko ; Kourtis, Iraklis C. ; van der Vlies, André J. ; Hubbell, Jeffrey A. ; Swartz, Melody A. / Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides : Cross-presentation and T cell activation. In: Vaccine. 2010 ; Vol. 28, No. 50. pp. 7897-7906.
@article{3d82d939a7a34b12895ff7f185b6a43b,
title = "Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation",
abstract = "Vaccines aiming to activate cytotoxic T cells require cross-presentation of exogenous antigen by antigen-presenting cells (APCs). We recently developed a synthetic nanoparticle vaccine platform that targets lymph node-resident dendritic cells (DCs), capable of mounting an immune response to conjugated antigen. Here, we explore routes of processing and the efficiency of MHC I cross-presentation of OVA peptides conjugated using both reducible and non-reducible linkages, exploring the hypothesis that reduction-sensitive conjugation will lead to better antigen cross-presentation. Both clathrin and macropinocytic pathways were implicated in nanoparticle uptake by colocalization and inhibitor studies. Cross-presentation by DCs was demonstrated by direct antibody staining and in vitro stimulation of CD8+ T cells from OT-I mice and was indeed most efficient with the reduction-sensitive conjugation. Similarly, we observed IFN-γ production by CD4+ T cells from OT-II mice. Finally, immunization with the OVA peptide-bearing nanoparticles resulted in in vivo proliferation and IFN-γ production by adoptively transferred CD8+ OT-I T cells and was also most efficient with reduction-sensitive linking of the peptide antigen. These results demonstrate the relevance of the poly(propylene sulfide) nanoparticle vaccine platform and antigen conjugation scheme for activating both cytotoxic and helper T cell responses.",
keywords = "Cross-presentation, Macropinocytosis, Nanoparticles, Reducible, Vinyl sulfone",
author = "Sachiko Hirosue and Kourtis, {Iraklis C.} and {van der Vlies}, {Andr{\'e} J.} and Hubbell, {Jeffrey A.} and Swartz, {Melody A.}",
year = "2010",
month = "11",
day = "23",
doi = "10.1016/j.vaccine.2010.09.077",
language = "English",
volume = "28",
pages = "7897--7906",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "50",

}

TY - JOUR

T1 - Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides

T2 - Cross-presentation and T cell activation

AU - Hirosue, Sachiko

AU - Kourtis, Iraklis C.

AU - van der Vlies, André J.

AU - Hubbell, Jeffrey A.

AU - Swartz, Melody A.

PY - 2010/11/23

Y1 - 2010/11/23

N2 - Vaccines aiming to activate cytotoxic T cells require cross-presentation of exogenous antigen by antigen-presenting cells (APCs). We recently developed a synthetic nanoparticle vaccine platform that targets lymph node-resident dendritic cells (DCs), capable of mounting an immune response to conjugated antigen. Here, we explore routes of processing and the efficiency of MHC I cross-presentation of OVA peptides conjugated using both reducible and non-reducible linkages, exploring the hypothesis that reduction-sensitive conjugation will lead to better antigen cross-presentation. Both clathrin and macropinocytic pathways were implicated in nanoparticle uptake by colocalization and inhibitor studies. Cross-presentation by DCs was demonstrated by direct antibody staining and in vitro stimulation of CD8+ T cells from OT-I mice and was indeed most efficient with the reduction-sensitive conjugation. Similarly, we observed IFN-γ production by CD4+ T cells from OT-II mice. Finally, immunization with the OVA peptide-bearing nanoparticles resulted in in vivo proliferation and IFN-γ production by adoptively transferred CD8+ OT-I T cells and was also most efficient with reduction-sensitive linking of the peptide antigen. These results demonstrate the relevance of the poly(propylene sulfide) nanoparticle vaccine platform and antigen conjugation scheme for activating both cytotoxic and helper T cell responses.

AB - Vaccines aiming to activate cytotoxic T cells require cross-presentation of exogenous antigen by antigen-presenting cells (APCs). We recently developed a synthetic nanoparticle vaccine platform that targets lymph node-resident dendritic cells (DCs), capable of mounting an immune response to conjugated antigen. Here, we explore routes of processing and the efficiency of MHC I cross-presentation of OVA peptides conjugated using both reducible and non-reducible linkages, exploring the hypothesis that reduction-sensitive conjugation will lead to better antigen cross-presentation. Both clathrin and macropinocytic pathways were implicated in nanoparticle uptake by colocalization and inhibitor studies. Cross-presentation by DCs was demonstrated by direct antibody staining and in vitro stimulation of CD8+ T cells from OT-I mice and was indeed most efficient with the reduction-sensitive conjugation. Similarly, we observed IFN-γ production by CD4+ T cells from OT-II mice. Finally, immunization with the OVA peptide-bearing nanoparticles resulted in in vivo proliferation and IFN-γ production by adoptively transferred CD8+ OT-I T cells and was also most efficient with reduction-sensitive linking of the peptide antigen. These results demonstrate the relevance of the poly(propylene sulfide) nanoparticle vaccine platform and antigen conjugation scheme for activating both cytotoxic and helper T cell responses.

KW - Cross-presentation

KW - Macropinocytosis

KW - Nanoparticles

KW - Reducible

KW - Vinyl sulfone

UR - http://www.scopus.com/inward/record.url?scp=78650231557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650231557&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.077

DO - 10.1016/j.vaccine.2010.09.077

M3 - Article

C2 - 20934457

AN - SCOPUS:78650231557

VL - 28

SP - 7897

EP - 7906

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -